
|Articles|June 29, 2013
Mechanism of Action: Herceptin (Trastuzumab)
The mechanism of action of trastuzumab (Herceptin), a monoclonal antibody that is approved for the treatment of early-stage breast cancer that is HER2-positive.
Advertisement
Trastuzumab (Herceptin) is a monoclonal antibody that interferes with the HER2/neu receptor. Herceptin is approved for the treatment of early-stage breast cancer that isHumanEpidermal growth factorReceptor2
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves T-DXd Plus Pertuzumab for HER2-Positive Breast Cancer
2
Teclistamab/Daratumumab Earns FDA Priority Voucher for R/R Myeloma
3
Roxadustat Granted Orphan Drug Designation for Myelodysplastic Syndromes
4
Breast Cancer Test Using Proteomic Profiling and AI Demonstrates High Performance
5








































